Breaking News Headlines Today | Ground News

See every side of every news story

targetedonc.com image

News from targetedonc.com

Ground News rates targetedonc.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, AllSides, and Media Bias/Fact Check.

Is targetedonc.com credible or reliable? Our Factuality score answers both of those questions. When it comes to targetedonc.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about targetedonc.com

Where is targetedonc.com located?targetedonc.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top targetedonc.com News

FDA Clears Larger Vial Size of Nelarabine Injection in T-ALL and T-LBL | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

United States · United States

FDA Clears Larger Vial Size of Nelarabine Injection in T-ALL and T-LBL | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

The FDA approves a larger vial of nelarabine injection, enhancing treatment flexibility for T-cell leukemia in adults and children.See the Story

FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

United States · United States

FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

The FDA granted fast track designation to a GPRC5D bispecific T-cell engager for multiple myeloma following positive safety and response outcomes in a dose escalation trial.See the Story

FDA Grants BTD to Bezuclastinib Combo in Gastrointestinal Stromal Tumors

FDA · United States

FDA Grants BTD to Bezuclastinib Combo in Gastrointestinal Stromal Tumors

Data from the phase 3 PEAK trial demonstrate that bezuclastinib plus sunitinib may be favorable vs sunitinib alone in certain patients with GISTs.See the Story

Breaking News Topics Related to targetedonc.com